Religiosity Versus Homosexuality in America (&amp; Elsewhere)

Osel, Joseph D.

doi:10.2139/ssrn.2907574

Cited by 1 publication

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Future clinical studies need to be performed to test the efficacy of CBM588 in preventing CDI recurrence. 125 MET-2 (Microbial Ecosystem Therapeutics 2) consists of a live microbe community derived from healthy donor stool developed by NuBiyota. A small 20-patient phase I pilot study (NCT02865616) is currently recruiting to test the safety and efficacy of MET-2 in treating recurrent CDI in patients who have experienced at least two prior C. difficile episodes.…”

Section: Antibodiesmentioning

confidence: 99%

Novel therapies and preventative strategies for primary and recurrent Clostridium difficile infections

Dieterle

Rao

Young

2018

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

Clostridium difficile is the leading infectious cause of antibiotic-associated diarrhea and colitis. Clostridium difficile infection (CDI) places a heavy burden on the health care system, with nearly half a million infections yearly and an approximate 20% recurrence risk after successful initial therapy. The high incidence has driven new research on improved prevention such as the emerging use of probiotics, intestinal microbiome manipulation during antibiotic therapies, vaccinations, and newer antibiotics that reduce the disruption of the intestinal microbiome. While the treatment of acute C. difficile is effective in most patients, it can be further optimized by adjuvant therapies that improve the initial treatment success and decrease the risk of subsequent recurrence. Lastly, the high risk of recurrence has led to multiple emerging therapies that target toxin activity, recovery of the intestinal microbial community, and elimination of latent C. difficile in the intestine. In summary, CDIs illustrate the complex interaction among host physiology, microbial community, and pathogen that requires specific therapies to address each of the factors leading to primary infection and recurrence.

show abstract

Section: Antibodiesmentioning

confidence: 99%